CMV423
≈ 1 min read
Names in other languages
- EnglishCMV423
- shCMV423
- СрпскиCMV423
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection and human herpesvirus 6 (HHV-6) infection. The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.
CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection and human herpesvirus 6 (HHV-6) infection. The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1148432242 under CC BY-SA 4.0; modifications have been made.